CV Lattes
ResearcherID
ORCID
Universidade de São Paulo (USP). Faculdade de Medicina de Ribeirão Preto (FMRP) (Institutional affiliation from the last research proposal) Birthplace: Brazil
graduation at Biology from Faculdade de Filosofia Ciências e Letras de Ribeirão Preto / USP (1987), m.sc. at Morfologia - Biologia Celular from Faculdade de Medicina de Ribeirão Preto - USP (1991) and ph.d. at Doutor em Ciências from Faculdade de Medicina de Ribeirão Preto - USP (1996). Has experience in Morphology, Molecular and Cell Biology, Cell Therapy and Cancer. At this moment, the research project is focussing in two different fiels using murine as animal models: 1) Cell Therapy for Hemophilia A and B using adult stem and progenitor cell and 2) Cancer with focus on tumor stroma with the objective to characterize cells from the bone marrow that contribute to tumor development and also the role of Hox genes in carcinogenesis using as a model meduloblastoma. Tem experiência nas áreas de Biotecnologia, Terapia Celular, Câncer e Biologia do Desenvolvimento, atuando nos seguintes temas: (1) Desenvolvimento de moléculas recombinantes e sintéticas da coagulação sangüínea humana (FVIII e FIX) utilizando vetores virais (retrovirus e lentivirus) em células humanas visando o tratamento de individuos portadores de Hemofilia A e B; (2) Desenvolvimento de protocolos pré-clinicos em camundongos hemofílicos A e B para investigar o papel das células-tronco ou progenitoras adultas no tratamento de Hemofilia A e B e contribuir para avaliar o impacto da terapia celular em doenças monogênicas; (3) Desenvolvimento de modelos murinos de tumores metastáticos e não metastáticos para investigações sobre o papel do estroma tumoral, das células da medula óssea e dos RNAs não codificadores na modulação dos genes HOX na progressão tumoral e (4) o papel funcional dos RNAs não codificadores na hematopoese. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
This proposal has two components: the research and educational. The research component focus on Gaucher disease, Gaucher disease is an autosomal recessive disease with a prevalence of 1:60,000 to 1:200,000 births. So far there is no cure, but there is treatment. Current treatments consist of replacement therapy with placenta-derived glucocerebrosidase (pdGBA) or recombinant glucocerebrosi…
Gaucher disease is an autosomal recessive disease with a prevalence of 1:60,000 to 1:200,000 births. So far there is no cure, but there is treatment. Current treatments consist of replacement therapy with placenta-derived glucocerebrosidase (pdGBA) or recombinant glucocerebrosidase (rGBA). Despite the advantages of rGBA compared to pdGBA, such as reduced risks of viral contamination, the …
Over the last 10-15 years, it has been recognized that development is a key for understanding tumor evolution. Many genes that control development are altered in cancer cells and have a role in neoplastic transformation. In this respect, homeobox genes (HOX) are primordial for development and their epigenetic deregulation is being progressively associated with tumor progression in leukemi…
Gaucher disease is characterized as an autosomal recessive disorder caused by mutations in the enzyme ²-glucocerebrosidase (GBA) gene. This disease has no cure, only treatment. One of the current treatment consists of replacement therapy via intravenous infusions of GBA placenta-derived (pGBA) or recombinant GBA (rGBa). Despite the advantages of rGBA compared to pGBA, such as reducing the…
Haemophilia A is a genetic X-linked disorder caused by the coagulation factor VIII (FVIII)deficiency. It affects 1 in 5,000 male births and is manifested by spontaneous bleeding or following trauma. The current treatment is the replacement therapy with plasma derived FVIII (pdFVIII) or recombinant FVIII (rFVIII). Despite the advantages of using rFVIII when compared to pdFVIII, as the lowe…
Over the last 10-15 years, it has been recognized that development is a key for understanding tumor evolution. Many genes that control development are altered in cancer cells and have implications in neoplastic transformation. In this respect, homeobox genes are primordial for development and their epigenetic deregulation is being progressively associated with tumor progression in various…
(Only some records are available in English at this moment)
SKP2 is the F-box protein of the E3 ubiquitin ligase complex that mediates target recognition and degradation of several cyclin-dependent kinase inhibitors as p27, p21 and p57, thus regulating cell cycle progression. Carlesso's group discovered that SKP2 is transcriptionally regulated by Notch signaling, and recently showed that SKP2 is overexpressed in pediatric T-cell acute lymphoblasti…
| 3 / 3 | Completed research grants |
| 8 / 5 | Completed scholarships in Brazil |
| 2 / 1 | Completed scholarships abroad |
| 13 / 9 | All research grants and scholarships |
| Associated processes | |